Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells

World Journal of Gastroenterology

Volumn 21, Issue 14, 2015, Pages 4169-4177

  Tsai, Cheng Chia ^a,b   Chuang, Tang Wei ^c   Chen, Li Jen ^d   Niu, Ho Shan ^e   Chung, Kun Ming ^c   Cheng, Juei Tang ^f   Lin, Kao Chang ^c,g  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^f CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^g SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Apoptosis; COLO 205; Colorectal cancer; Mammol Lalian target of rapamycin; Metformin; Silibinin

Indexed keywords

ADENOSINE PHOSPHATE; APOPTOSIS INDUCING FACTOR; CASPASE 3; METFORMIN; PHOSPHATASE; SILIBININ; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SILYMARIN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; EPITHELIUM CELL; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; METFORMIN; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SILYMARIN; TOR SERINE-THREONINE KINASES;

EID: 84927614562     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i14.4169     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29 [PMID: 24399786 doi: 10.3322/caac.21208]
2. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ieranò C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, Scala S. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12: 2795-2803 [PMID: 16675573 doi: 10.1158/1078-0432.CCR-05-2142]
3. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008; 15: 1044-1071 [PMID: 18473802 DOI: 10.2174/092986708784221403]
4. Wu H, Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Smalley WE, Chen H, Li M, Shyr Y, Zheng W. Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr 2009; 139: 340-344 [PMID: 19091801 doi: 10.3945/jn.108.098889]
5. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009; 8: 2366-2374 [PMID: 19638451 doi: 10.1158/1535-7163.MCT-09-0304]
6. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-119 [PMID: 17548790]
7. Gazák R, Walterová D, Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 2007; 14: 315-338 [PMID: 17305535 doi: 10.2174/092986707779941159]
8. Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med 2013; 27: 10-16 [PMID: 23140176 doi: 10.1111/jvim.12002]
9. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol Carcinog 2004; 40: 143-149 [PMID: 15224346 doi: 10.1002/mc.20018]
10. Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15: 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943]
11. Mohan S, Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin modulates UVB-induced apoptosis via mitochondrial proteins, caspases activation, and mitogen-activated protein kinase signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun 2004; 320: 183-189 [PMID: 15207719 DOI: 10.1016/j.bbrc.2004.05.153]
12. Yang SH, Lin JK, Chen WS, Chiu JH. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J Surg Res 2003; 113: 133-138 [PMID: 12943822 doi: 10.1016/S0022-4804(03)00229-4]
13. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62: 3063-3069 [PMID: 12036915]
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174 [PMID: 11602624 doi: 10.1172/JCI13505]
15. Lee H, Park HJ, Park CS, Oh ET, Choi BH, Williams B, Lee CK, Song CW. Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One 2014; 9: e87979 [PMID: 24505341 doi: 10.1371/journal.pone.0087979]
16. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012; 5: 355-364 [PMID: 22086681 DOI: 10.1158/1940-6207.CAPR-11-0299]
17. Kato K, Gong J, Iwama H, Kitanaka A, Tani J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, Kobara H, Mori H, Himoto T, Okano K, Suzuki Y, Murao K, Masaki T. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-560 [PMID: 22222629 doi: 10.1158/1535-7163.MCT-11-0594]
18. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-693 [PMID: 16125352 doi: 10.1016/j.exger.2005.07.007]
19. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586 [PMID: 18212742 doi: 10.1038/sj.onc.1211024]
20. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13: 483-491 [PMID: 21532889]
21. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D, Trajkovic V. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 2011; 668: 373-382 [PMID: 21806981 doi: 10.1016/j.ejphar.2011.07.004]
22. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and metaanalysis. PLoS One 2012; 7: e33411 [PMID: 22448244 DOI: 10.1371/journal.pone.0033411]
23. Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev 2013; 22: 1877-1883 [PMID: 23966577 doi: 10.1158/1055-9965. EPI-13-0196]
24. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143-156 [PMID: 24393785 doi: 10.1038/nrendo.2013.256]
25. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13: 5299-5305 [PMID: 17879397 doi: 10.3748/wjg.v13.i40.5299]
26. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 2007; 17: 461-480 [PMID: 17479394 doi: 10.1080/10543400701199593]
27. Yu HC, Chen LJ, Cheng KC, Li YX, Yeh CH, Cheng JT. Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog. Phytother Res 2012; 26: 709-715 [PMID: 22016029 doi: 10.1002/ptr.3618]
28. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-2963 [PMID: 15254063 doi: 10.1200/JCO.2004.02.141]
29. Su CH, Chen LJ, Liao JF, Cheng JT. Increase of phosphatase and tensin homolog by silymarin to inhibit human pharynx squamous cancer. J Med Food 2013; 16: 778-784 [PMID: 23909904 DOI: 10.1089/jmf.2012.2534]
30. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NFkappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005; 24: 1188-1202 [PMID: 15558015 DOI: 10.1038/sj.onc.1208276]
31. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of betacatenin-dependent signaling. Neoplasia 2010; 12: 415-424 [PMID: 20454513]
32. Dilman VM. Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageine, and disease. Lancet 1971; 1: 1211-1219 [PMID: 4103080]
33. Berstein LM, Boyarkina MP, Teslenko SY. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med Oncol 2012; 29: 1308-1313 [PMID: 21298495 doi: 10.1007/s12032-011-9840-0]
34. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 2011; 121: 492-498 [PMID: 21388661 doi: 10.1016/j.ygyno.2011.02.021]
35. Ma J, Guo Y, Chen S, Zhong C, Xue Y, Zhang Y, Lai X, Wei Y, Yu S, Zhang J, Liu W. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma. BMC Cancer 2014; 14: 172 [PMID: 24612549 doi: 10.1186/1471-2407-14-172]
36. Kusmic C, L'abbate A, Sambuceti G, Drummond G, Barsanti C, Matteucci M, Cao J, Piccolomini F, Cheng J, Abraham NG. Improved myocardial perfusion in chronic diabetic mice by the upregulation of pLKB1 and AMPK signaling. J Cell Biochem 2010; 109: 1033-1044 [PMID: 20108250 doi: 10.1002/jcb.22486]
37. Oudejans JJ, Muris JJ, Meijer CJ. Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Cell Cycle 2005; 4: 526-528 [PMID: 15876872]
38. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 2008; 14: 7192-7198 [PMID: 19084933 doi: 10.3748/wjg.14.7192]
39. Kauntz H, Bousserouel S, Gossé F, Raul F. Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis 2011; 16: 1042-1053 [PMID: 21779837 DOI: 10.1007/s10495-011-0631-z]
40. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273 [PMID: 17062558 doi: 10.1158/0008-5472.CAN-06-1500]
41. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9: 1057-1064 [PMID: 20305377 doi: 10.4161/cc.9.6.10994]
42. Yang CH, Craise LM. Development of human epithelial cell systems for radiation risk assessment. Adv Space Res 1994; 14: 115-120 [PMID: 11538024 doi: 10.1016/0273-1177(94)90459-6]